IC7, an innovative designer gp130 cytokine and its acute mode of action<em></em> — ASN Events
  1. Schedule
  2. ADS Basic Orals: Lipids, Cytokines and Glucose Tolerance
  3. IC7, an innovative designer gp130 cytokine and its acute mode of action

IC7, an innovative designer gp130 cytokine and its acute mode of action (#194)

Maria Findeisen 1 , Tamara L Allen 1 , Lena Cron 1 , Helene Kammoun 1 , Darren C Henstridge 1 , Guy Krippner 1 , Tim Adams 2 , Stefan Rose-John 3 , Mark A Febbraio 4
  1. Bakeridi Heart and Diabetes Institute, Melbourne, VIC, Australia
  2. Molecular and Health Technologies, CSIRO, Parkville, VIC, Australia
  3. Department of Biochemistry, Christian-Albrechts-Universität, Kiel, Germany
  4. Cellular and Molecular Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, NSW, Australia
Publish consent withheld
  1. Carey, A.L., et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. in Diabetes, Vol. 55 2688-2697 (2006).
  2. Watt, M.J., et al. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. in Nat Med, Vol. 12 541-548 (2006).
  3. Febbraio, M.A. gp130 receptor ligands as potential therapeutic targets for obesity. in J Clin Invest, Vol. 117 841-849 (2007).